GLYCONEX INCORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.3 TWD | -0.78% |
|
+0.40% | -14.96% |
| Sales 2022 | 30.08M 930K 73.99M | Sales 2023 | 2.54M 78.55K 6.25M | Capitalization | 3.22B 99.47M 7.92B |
|---|---|---|---|---|---|
| Net income 2022 | -220M -6.8M -541M | Net income 2023 | -178M -5.5M -438M | EV / Sales 2022 | 93.3 x |
| Net cash position 2022 | 455M 14.06M 1.12B | Net cash position 2023 | 700M 21.62M 1.72B | EV / Sales 2023 | 991 x |
| P/E ratio 2022 |
-13.8
x | P/E ratio 2023 |
-18
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.01% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.78% | ||
| 1 week | +0.40% | ||
| Current month | +1.20% | ||
| 1 month | +1.20% | ||
| 3 months | -6.64% | ||
| 6 months | -13.21% | ||
| Current year | -14.96% |
1 week
25.30
26.00
1 month
24.8528.65
Current year
24.1529.75
1 year
24.1533.45
3 years
23.6046.90
5 years
10.2046.90
10 years
10.20110.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mei Chun Yang
CEO | Chief Executive Officer | - | 31/12/06 |
Tong Hsuan Chang
FOU | Founder | - | 31/01/01 |
Dih Fen Wu
DFI | Director of Finance/CFO | - | 31/12/09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kao Chung Tsai
BRD | Director/Board Member | 62 | - |
Tong Hsuan Chang
FOU | Founder | - | 31/01/01 |
Ling-Chun Tsai
BRD | Director/Board Member | - | 24/05/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 25.3 | -.--% | 151,765 |
| 30/04/24 | 25.3 | -0.78% | 282,669 |
| 29/04/24 | 25.5 | -.--% | 142,607 |
| 26/04/24 | 25.5 | +0.39% | 253,326 |
| 25/04/24 | 25.4 | -0.78% | 128,476 |
End-of-day quote Taipei Exchange, April 29, 2024
More quotes
GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.96% | 84.42M | |
| +26.28% | 42.68B | |
| -3.99% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +6.36% | 24.94B | |
| -21.47% | 18.96B | |
| +27.58% | 12.3B | |
| -2.75% | 11.95B | |
| -2.02% | 11.55B |
- Stock Market
- Equities
- 4168 Stock
